Cargando…

Hyperthermia combined with immune checkpoint inhibitor therapy in the treatment of primary and metastatic tumors

According to the difference in temperature, thermotherapy can be divided into thermal ablation and mild hyperthermia. The main advantage of thermal ablation is that it can efficiently target tumors in situ, while mild hyperthermia has a good inhibitory effect on distant metastasis. There are some si...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Ximing, Gao, Miaozhi, Xu, Runshi, Tao, Yangyang, Luo, Wang, Wang, Binya, Zhong, Wenliang, He, Lan, He, Yingchun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412234/ https://www.ncbi.nlm.nih.gov/pubmed/36032103 http://dx.doi.org/10.3389/fimmu.2022.969447

Ejemplares similares

Analysis of the Molecular Mechanism of Evodia rutaecarpa Fruit in the Treatment of Nasopharyngeal Carcinoma Using Network Pharmacology and Molecular Docking
por: Xu, Runshi, et al.
Publicado: (2022)

Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors
por: Li, Zihui, et al.
Publicado: (2020)

Analysis of active components and molecular mechanism of action of Rubia cordifolia L. in the treatment of nasopharyngeal carcinoma based on network pharmacology and experimental verification
por: Yang, Ximing, et al.
Publicado: (2023)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes
por: Liu, Pengyuan, et al.
Publicado: (2022)

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma
por: Zhong, Yu-Min, et al.
Publicado: (2022)

Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy
por: Johansen, Astrid Z., et al.
Publicado: (2023)

Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
por: He, Danming, et al.
Publicado: (2023)

Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis
por: Wang, He, et al.
Publicado: (2022)

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
por: Yan, Yiyi, et al.
Publicado: (2018)

Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response
por: Yang, Fei, et al.
Publicado: (2022)

Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis
por: Feng, Yao-Ning, et al.
Publicado: (2023)

The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment
por: Shi, Ming-Yan, et al.
Publicado: (2023)

Analysis of Tumor Microenvironment Characteristics in Bladder Cancer: Implications for Immune Checkpoint Inhibitor Therapy
por: Chen, Xingyu, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management
por: Tang, Liansha, et al.
Publicado: (2021)

Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions
por: Jiang, Mengjie, et al.
Publicado: (2023)

Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors
por: Liu, Wenhui, et al.
Publicado: (2021)

Unsatisfied Reporting Quality of Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy in Cancer
por: Chen, Chen, et al.
Publicado: (2021)

Immune depletion of the methylated phenotype of colon cancer is closely related to resistance to immune checkpoint inhibitors
por: Zhong, Chengqian, et al.
Publicado: (2022)

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
por: Song, Yuxiao, et al.
Publicado: (2020)

Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer
por: He, Jiahui, et al.
Publicado: (2023)

The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent
por: Grasselly, Chloé, et al.
Publicado: (2018)

Development of a prognostic model to identify the metastatic nasopharyngeal carcinoma patients who may benefit from chemotherapy combination PD-1 inhibitor
por: Liu, Guo-Ying, et al.
Publicado: (2023)

Imaging Mass Cytometry Analysis of immune Checkpoint Inhibitor-Related Pneumonitis: A Case Report
por: Cheng, Yuan, et al.
Publicado: (2022)

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
por: Khair, Duaa O., et al.
Publicado: (2019)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
por: Han, Rui, et al.
Publicado: (2023)

Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy
por: Pickering, Chad, et al.
Publicado: (2023)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma
por: Li, Xiaomi, et al.
Publicado: (2022)

Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer
por: He, Shengxiu, et al.
Publicado: (2023)

Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy
por: Wu, Jianmin, et al.
Publicado: (2021)

Enhancing the abscopal effect of radiation and immune checkpoint inhibitor therapies with magnetic nanoparticle hyperthermia in a model of metastatic breast cancer
por: Oei, Arlene L., et al.
Publicado: (2019)

PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis
por: Khan, Muhammad, et al.
Publicado: (2023)

Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
por: Zhou, Xiaoting, et al.
Publicado: (2022)

The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors
por: Tong, Huan, et al.
Publicado: (2022)

Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma
por: Zhang, Zhuochao, et al.
Publicado: (2023)

Multi-Omics Profiling Identifies Risk Hypoxia-Related Signatures for Ovarian Cancer Prognosis
por: Chen, Xingyu, et al.
Publicado: (2021)

Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study
por: Jiang, Nan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4q2ns1egr3kar4sniepe8k52oj